蝮蛇抗栓酶治疗心血管疾病40例

Ahalysantinfarctase modifying the cardiovascular disease in 40 patients

应用蝮蛇抗栓酶(由江浙蝮蛇毒中提取)治疗心血管疾病40例,剂量为0.01-0.02U/kg,稀释后静滴,qd,21d为一疗程。治疗后患者的全血和血浆粘度、血小板聚集率、纤维蛋白原含量和血脂浓度均有显著下降。另有类似的40例患者用曲克芦丁400mg/d,静滴,21d为一疗程作对照,结果发现蝮蛇抗栓酶组(包括临床疗效)均明显优于对照组,且不良反应轻微,未发现肝、肾功能障碍和明显出血倾向。

A preparation of ahalysantinfarctase (from snake venom of the Pallas pit viper in Jiangsu and Zhejiang Provinces), 0.01-0.02 U/kg, for intravenous drip after dilution once daily, 21 d as a course of treatment, was given to 40 patients with various cardiovascular disease The blood and plasma viscosity, the fibrinogen content, the rate of platelet aggregation and the blood Hpid's concentration were all decreased significantly following the medication. Another 40 patients with similar disease receiving troxerutin, 400 mg/d, also via intravenous drip, however had less remarkable advantages.Clinical efficacy was far better in the former than in the latter. The adverse reactions were mild, no hepatic or renal impairments and no marked bleeding tendency were observed